Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Regenxbio (RGNX) EPS (Basic) (2016 - 2025)

Regenxbio (RGNX) has 12 years of EPS (Basic) data on record, last reported at -$1.3 in Q4 2025.

  • For Q4 2025, EPS (Basic) fell 30.0% year-over-year to -$1.3; the TTM value through Dec 2025 reached -$3.76, up 18.26%, while the annual FY2025 figure was -$3.76, 18.08% up from the prior year.
  • EPS (Basic) reached -$1.3 in Q4 2025 per RGNX's latest filing, down from -$1.2 in the prior quarter.
  • Across five years, EPS (Basic) topped out at $6.94 in Q4 2021 and bottomed at -$1.79 in Q1 2022.
  • Average EPS (Basic) over 5 years is -$0.89, with a median of -$1.38 recorded in 2021.
  • The widest YoY moves for EPS (Basic): up 664.23% in 2021, down 670.83% in 2021.
  • A 5-year view of EPS (Basic) shows it stood at $6.94 in 2021, then crashed by 119.88% to -$1.38 in 2022, then dropped by 2.9% to -$1.42 in 2023, then rose by 29.58% to -$1.0 in 2024, then crashed by 30.0% to -$1.3 in 2025.
  • Per Business Quant database, its latest 3 readings for EPS (Basic) were -$1.3 in Q4 2025, -$1.2 in Q3 2025, and -$1.38 in Q2 2025.